AstraZeneca's Imfinzi Immunotherapy Gets U.S. FDA Approval for Endometrial Cancer
By Elena Vardon
AstraZeneca said the U.S. Food and Drug Administration approved the use of its Imfinzi immunotherapy along with chemotherapy for endometrial cancer.
The British-Swedish pharma giant said Monday that it received approval in the U.S. for the drug--in combination with carboplatin and paclitaxel followed by Imfinzi monotherapy--to be used to treat adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient.
The FDA gave the group the green light based on the results of its DUO-E Phase 3 trial, which showed Imfinzi reduced the risk of disease progression or death by 58% against chemotherapy alone, AstraZeneca said.
Write to Elena Vardon at elena.vardon@wsj.com
(END) Dow Jones Newswires
June 17, 2024 02:29 ET (06:29 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Best- and Worst-Performing Stocks of Q2 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations